AACR-Novocure Career Development Award for Cancer Research
Supports early-career researchers using the Inovitro® system to study Tumor Treating Fields for innovative basic or translational cancer research, with emphasis on novel mechanisms and combination therapies.
Funder: American Association for Cancer Research
Due Dates (Anticipated): May 2026 (Letter of Intent) | June 2026 (Full Application) | September 2026 (Full Application, projected)
Funding Amounts: $300,000 total over 3 years; supports PI salary, personnel, supplies, equipment, limited travel, and indirect costs (max 10%).
Summary: Supports early-career researchers advancing innovative cancer research using Tumor Treating Fields, with required use of the Inovitro® system.
Key Information: All dates are projected based on the annual cycle; check the program page for updates.
Description
This award is designed to support early-career investigators conducting innovative research on Tumor Treating Fields (TTFields)—an emerging cancer therapy using intermediate frequency, low-intensity, alternating electric fields to disrupt cancer cell division. Projects must incorporate the Inovitro® system (provided and supported by Novocure if needed) into the experimental design. Research may be basic or translational, with preference for studies that move in vitro findings in vivo, explore TTFields in combination with other therapies, or facilitate clinical translation. Inter-laboratory collaboration is encouraged, particularly for those new to TTFields research. Key areas of interest include cancer-related signaling pathways, metabolic effects, omics data integration, immunological aspects, and combination studies with approved agents.
